Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Japan PM’s Advisers Urge Annual Review of Drug Prices

Reuters Staff  |  December 8, 2016

TOKYO (Reuters)—Prime Minister Shinzo Abe’s economic advisers, hoping to curb Japan’s ballooning healthcare costs, proposed on Wednesday reforms to the way drug prices are set, a step opposed by foreign and domestic drug makers who say the changes will stifle investment.

The proposals follow a decision to halve the price of Bristol Myers Squibb Co’s cancer drug Opdivo (nivolumab) last month, and an earlier move to slash the price of Gilead Science Inc’s highly effective, but expensive, hepatitis C drug Sovaldi (sofosbuvir).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The four private-sector advisers at Abe’s Council on Economic and Fiscal Policy (CEFP) proposed reviewing all prescription drug prices, which are set by the government, at least annually, rather than once every two years as currently.

The advisers, including Sadayuki Sakakibara, head of Japan’s biggest business lobby Keidanren, went on to call for reviewing four times a year official prices of the drugs that prove to be effective against more diseases than initially identified and which experience an unexpectedly high surge in sales.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Health Minister Yasuhisa Shiozaki put forward a similar proposal at the panel’s meeting on Wednesday.

Based on the private-sector advisers’ proposals, Abe ordered Economy Minister Nobuteru Ishihara and other cabinet ministers to map out basic guidelines by the next panel meeting later this month.

Abe’s advisers also called for reviewing prices on generic drugs once a year or more, which would lead to lower official prices given that market prices of medicines overall are on a steady decline.

Japanese and foreign drug makers argue that not only would the changes stifle innovation by creating uncertainty over pricing, but would undercut a key component of Abe’s economic growth policy, which calls for attracting research and development investment from pharmaceutical companies.

“The current system of biennial repricing has served Japan and the Japanese people well by ensuring the predictability of reimbursement, controlling healthcare expenditures, rewarding innovation and, most importantly, improving access for Japanese patients to the most innovative treatments available globally,” says a joint statement by U.S. and European industry groups.

“Adopting annual repricing threatens to undo all of these achievements,” the statement says, echoing complaints by Japanese drugmakers.

Share: 

Filed under:Drug Updates Tagged with:costsdrugdrug pricingInternationalJapanpharmaceutical company

Related Articles

    Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices

    January 11, 2019

    WASHINGTON (Reuters)—U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. Democrats have been critical of efforts by the Trump administration to bring down drug prices after President Donald Trump promised to do so during his campaign and since being…

    Clinical Trials Go Global

    November 1, 2011

    As medical research expands to the global population, will trial results sill apply to U.S. populations?

    When Rheumatic Disease May Have Affected the Course of Western Civilization

    November 8, 2022

    The study of rheumatology (and medicine) in art, history, literature and music is engaging and informative.1-12 In this article, we present some instances when rheumatic and autoimmune diseases in certain individuals may have affected the course of history in Western civilization. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEPhysicians are usually concerned, appropriately, with the effects of illness…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences